Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

Stroma decreases spheroid size by decreasing cell width. by Karen F. Chambers (224337)

Decreased oscillatory flow decreases <i>klf2a</i> expression. by Julien Vermot (257990)

“…<p>(A) RFF is decreased by alterations in heart rate. …”

Hyperalgesia was assessed by a decrease in paw withdrawal threshold (PWT_50%) in a model of mild heat injury (MHI). by Manuel P. Pereira (417488)

Downregulation of DOM decreases the abundance of PER and TIM. by Zhenxing Liu (399809)

“…Downregulation of DOM decreased PER levels at CT1-5 and CT17-21. (Scale bar: 50 um.) …”

Mesothelin expression and RG7787 uptake is decreased in KLM-1-R. by Kevin Hollevoet (710450)

“…<p><b>A</b>: Surface mesothelin levels are 5-fold lower in resistant KLM-1 (KLM-1-R) compared to KLM-1. …”

Bacterial co-abundance networks decreases in complexity with lower host genetic variation. by Michael Ørsted (5926028)

The distributions of the end-simulation adolescence-limited proportion when (a) <i>k</i> is increased or decreased by 50%, (b) <i>c</i> is increased or decreased by 50%, (c) <i>γ</i> is increased or decreased by 50%, and (d) Δ<i>e</i> is increased or decreased by 50%, compared against the benchmark distribution <i>F</i>(<b>p</b>₀) for the parameters shown in Table 1. by Jia Ning Leaw (752775)

PowerPoint Slides for: Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis by Bushinsky D.A. (3246690)

Population dynamics modeling of split^50cM <i>ClvR</i> V1 introduced at a 50% release, with fitness cost per allele varying from 0–15%. by Georg Oberhofer (3401438)

Expression of ApoB-50 decreased lipid accumulation and inhibited HCV production. by Bei Wang (116772)

NFκB-p50 knockdown decreases CD44 expression. by Shannon M. Smith (115335)

Prevalence and anatomic level of stenosis ≥ 50% in either limb. by O. Stivalet (6890189)

Affinity analysis results (with a confidence level above 50%). by Marta R. Jabłońska (8491404)

mGluR5 receptor decreased glycinergic currents. by Zi-Yang Zhang (4988555)

“…(<b>E</b>) The inhibitory effect of CHPG on GlyR-IPSCs was not blocked by intracellularly loaded GDP-β-S (62.3 ± 6.4% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.782, <i>p</i> = 0.032), chelerythrine (60.9 ± 11.3% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.705, <i>p</i> = 0.035), or Ro-32-0432 (69.9 ± 3.2% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 8.495, <i>p</i> < 0.001). (<b>F</b>) Postsynaptic loading of U-0126 or PD98059 prevented CHPG from decreasing glycinergic responses (U-0126, 107.6 ± 10.4% of baseline at 15–20 min post-CHPG, <i>t</i>[8] = 0.997, <i>p</i> = 0.348; PD98059, 93.1 ± 5.0% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 0.883, <i>p</i> = 0.418). …”

Damsin (D) and ambrosin (A) treatment decreases the CSC population. by Wendy Soria Sotillo (4408105)

EC50 and percentage decrease in intracellular <i>Listeria</i> viability for effective compounds. by Marie-Eve Charbonneau (5658799)

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”

Behavior of split^<50cM <i>ClvR</i> V2 with linkage. by Georg Oberhofer (3401438)

“…<p>Incorporating linkage into split <i>ClvR</i> (split^<50cM <i>ClvR</i> V2) results in a graded increase in drive strength, and duration of <i>Rescue</i>/Cargo/gRNAs at high frequency, as the degree of linkage increases (map distance decreases). …”

Behavior of split^<50cM <i>ClvR</i> V1 with linkage. by Georg Oberhofer (3401438)